Doubling the response rate in a population with few options
In the long and often humbling effort to extend human life against cancer, a Boston-based company called Compass Therapeutics enters 2026 with several experimental medicines at pivotal crossroads. Across biliary tract cancer, triple-negative breast cancer, Hodgkin Lymphoma, and colorectal cancer, the company is accumulating early signals that its bispecific antibody approach may offer something meaningful where few options remain. The coming months will test whether those signals harden into proof — and whether patients who have run out of standard treatments might find a new path forward.
- Patients with advanced cancers who have exhausted standard therapies represent an urgent, underserved population, and Compass is betting its pipeline can reach them where existing drugs fall short.
- Tovecimig's 5% response rate in heavily pre-treated colorectal cancer patients — against a field where rivals manage only 1 to 1.5% — has raised the stakes for its upcoming biliary tract cancer survival readout expected in late spring 2026.
- CTX-8371's rare ability to produce responses in both a blood cancer and a solid tumor has disrupted the company's own roadmap, prompting it to pursue accelerated regulatory approval in Hodgkin Lymphoma while simultaneously expanding enrollment in breast and lung cancer trials.
- The company is navigating the transition from research organization to commercial enterprise, hiring a Chief Commercial Officer and Chief Medical Officer with track records of actually launching oncology drugs.
- With $209 million in cash secured through 2028 and multiple data milestones converging in 2026, Compass is positioned to sustain its multi-front campaign — though the biliary tract survival numbers remain the defining test of whether its lead drug earns a regulatory filing by year's end.
Compass Therapeutics began 2026 with its experimental cancer medicines at critical decision points. The Boston company's lead drug, tovecimig, is expected to deliver survival data from a biliary tract cancer trial in late spring — a readout that could support the company's first regulatory filing before the year is out. Biliary tract cancer offers patients few effective treatments, making any meaningful survival benefit significant.
Tovecimig, which blocks two proteins involved in tumor growth and blood vessel formation, has already shown activity in colorectal cancer patients who had failed all prior therapies, including multiple rounds of bevacizumab. Two of forty such patients responded — a 5% rate that, while modest in absolute terms, meaningfully exceeds the 1 to 1.5% seen with comparable drugs in this population. Side effects have been manageable, with elevated blood pressure the most common concern.
The company's second program, CTX-8371, has produced an unexpected finding: it appears to work in both solid tumors and blood cancers. A triple-negative breast cancer patient has maintained a deepening partial response for thirty-two weeks, while a third confirmed response has now emerged in a Hodgkin Lymphoma patient. That dual activity has led Compass to explore accelerated approval pathways for Hodgkin Lymphoma — including in pediatric patients — who have already failed checkpoint inhibitor therapy. Expanded enrollment is underway in breast and lung cancer cohorts.
A third candidate, CTX-10726, enters human trials in early 2026, with preliminary results expected by mid-year. Laboratory studies suggest it outperforms a competitor in the same drug class on both tumor control and immune activation.
To prepare for potential commercialization, Compass recruited two senior leaders: a Chief Commercial Officer who has previously launched oncology drugs including one for biliary tract cancer, and a Chief Medical Officer with extensive clinical development experience. The company closed 2025 with $209 million in cash, providing a financial runway into 2028 — enough time to see its most important trials through to their conclusions.
Compass Therapeutics, a Boston-based drug developer, is moving through 2026 with a slate of experimental cancer treatments at critical junctures. The company announced on January 6 that its lead candidate, tovecimig, is on track to deliver survival data in late spring—the kind of readout that can reshape how doctors treat biliary tract cancer, a disease with few good options. If those numbers hold, the company plans to file its first regulatory application by year's end.
Tovecimig works by targeting two proteins involved in tumor growth and blood vessel formation. The company has already shown it can shrink tumors in patients with advanced colorectal cancer who have exhausted standard treatments. In a study of forty heavily pre-treated patients—all of whom had received the anti-cancer drug bevacizumab before, many multiple times—tovecimig produced responses in two patients, a 5 percent rate. That may sound modest, but it outpaces what other similar drugs achieve in this population, which typically see response rates between 1 and 1.5 percent. The drug's safety profile has been manageable, with high blood pressure as the most common side effect, mostly in patients who already had hypertension.
The company's second major program, CTX-8371, is showing something unexpected: it works in both solid tumors and blood cancers. In early testing, it produced a deep partial response in a patient with triple-negative breast cancer that has held steady for thirty-two weeks and continues to improve. More striking, a third confirmed response appeared in a patient with Hodgkin Lymphoma, a blood cancer. This dual activity has prompted Compass to explore faster regulatory pathways for approval in Hodgkin Lymphoma patients, both adults and children, who have already failed checkpoint inhibitor therapy—the current standard treatment. The company is now enrolling expanded patient groups with triple-negative breast cancer and non-small cell lung cancer to gather more evidence.
A third drug, CTX-10726, is entering human testing in the first quarter of 2026, with initial results expected by mid-year. In laboratory and animal studies, it showed stronger tumor control than a competing drug in the same class and more potent immune activation. The company is also preparing to launch a Phase 2 trial of CTX-471, a different type of immune-activating antibody, in patients with tumors that express a specific marker.
Compass has bolstered its leadership to handle what comes next. Arjun Prasad, who has launched multiple oncology drugs including a treatment for biliary tract cancer, joined as Chief Commercial Officer. Cynthia Sirard, an oncology physician with deep experience in clinical development, became Chief Medical Officer. Their arrivals signal the company's confidence that it will have drugs to commercialize, not just research to conduct.
Financially, the company has $209 million in cash and securities as of the end of 2025, enough to fund operations into 2028. That runway matters because drug development is a long game—failures are common, timelines slip, and the path from early testing to approval can take years. Compass will present its strategy to investors at the J.P. Morgan Healthcare Conference on January 14, and tovecimig data will be presented at an oncology conference on January 9. The real test comes in late spring, when the biliary tract cancer survival numbers arrive. Until then, the company is positioned to advance multiple shots on goal across different cancer types and patient populations.
Citas Notables
Key survival analyses for tovecimig in late Q1, if positive, could transform the treatment of patients with biliary tract cancer.— Thomas Schuetz, MD, PhD, CEO and Vice Chairman
We are glad to be in a position to deliver true innovation for patients and hope to make a meaningful difference in these difficult-to-treat cancers.— Thomas Schuetz, MD, PhD, CEO and Vice Chairman
La Conversación del Hearth Otra perspectiva de la historia
Why does a 5 percent response rate in colorectal cancer matter when it sounds so small?
Because in this patient population—people who've already failed multiple rounds of bevacizumab—you're not expecting much. Other drugs in this class get 1 to 1.5 percent. When you double or triple that, it's a signal that something is working differently.
What makes CTX-8371 unusual?
It's working in both solid tumors and blood cancers. Most drugs are good at one or the other. Seeing a response in Hodgkin Lymphoma alongside responses in breast cancer suggests the mechanism is broader than anyone predicted. That's why they're looking at accelerated approval pathways.
Accelerated approval—what does that mean for patients?
It means the FDA can approve a drug based on earlier evidence if it addresses an unmet need. For Hodgkin Lymphoma patients who've already failed checkpoint inhibitors, there aren't many options left. If CTX-8371 keeps showing activity, it could reach those patients years sooner than the standard approval process would allow.
The company hired two senior executives. Is that a sign of confidence or desperation?
Confidence. You don't hire a Chief Commercial Officer unless you believe you'll have products to sell. Prasad has actually launched a biliary tract cancer drug before, so he knows the market and the regulatory landscape. That's not a generic hire.
What's the risk here?
Clinical trials fail. The biliary tract cancer survival data in late Q1 could disappoint. CTX-8371 might not hold up in larger patient groups. The company has runway into 2028, but if the data doesn't support the pipeline, that cash depletes fast.
Why does the company have three different drugs in development at once?
Diversification. If one fails, the others might succeed. And they're targeting different mechanisms—blood vessel formation, immune activation, different immune pathways. It's a portfolio strategy, not a bet on a single molecule.